CARDIFF ONCOLOGY, INC. Restructuring Costs and Asset Impairment Charges
CARDIFF ONCOLOGY, INC. (CRDF) reported Restructuring Costs and Asset Impairment Charges of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Cash Flow › Operating Activities
us-gaap:RestructuringCostsAndAssetImpairmentCharges · last filed 2022-02-24
- CARDIFF ONCOLOGY, INC. restructuring costs and asset impairment charges for the quarter ending 2019-12-31 was $0.00.
- CARDIFF ONCOLOGY, INC. restructuring costs and asset impairment charges for the quarter ending 2019-09-30 was $0.00.
- CARDIFF ONCOLOGY, INC. restructuring costs and asset impairment charges for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. restructuring costs and asset impairment charges for the quarter ending 2018-09-30 was $0.00.
- CARDIFF ONCOLOGY, INC. restructuring costs and asset impairment charges for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- CARDIFF ONCOLOGY, INC. restructuring costs and asset impairment charges for fiscal 2020 was $34.00K.
- CARDIFF ONCOLOGY, INC. restructuring costs and asset impairment charges for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- CARDIFF ONCOLOGY, INC. restructuring costs and asset impairment charges for fiscal 2018 was $187.50K, a 68.20% decline from fiscal 2017.
| Period end | Restructuring Costs and Asset Impairment Charges 3 month | Restructuring Costs and Asset Impairment Charges 6 month | Restructuring Costs and Asset Impairment Charges 9 month | Restructuring Costs and Asset Impairment Charges 12 month | Restructuring Costs and Asset Impairment Charges 12 month as first filed |
|---|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-24 | ||||
| 2020-12-31 | $34.00K 10-K · filed 2022-02-24 | $34.17K 10-K · filed 2021-02-25 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $0.00 derived: sum of 2 quarters · filed 2021-02-25 | $0.00 10-K · filed 2021-02-25 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-08 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $187.50K derived: sum of 3 quarters · filed 2020-02-27 | $187.50K 10-K · filed 2020-02-27 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $187.50K derived: sum of 2 quarters · filed 2019-11-07 | $187.50K 10-Q · filed 2019-11-07 | $292.20K derived: sum of 4 quarters · filed 2019-11-07 | |
| 2018-06-30 | $187.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $187.50K 10-Q · filed 2019-08-08 | $292.20K derived: sum of 3 quarters · filed 2019-08-08 | $292.20K derived: sum of 4 quarters · filed 2019-08-08 | |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-08 | $104.70K derived: sum of 2 quarters · filed 2019-03-06 | $104.70K derived: sum of 3 quarters · filed 2019-03-06 | $104.70K derived: sum of 4 quarters · filed 2019-03-06 | |
| 2017-12-31 | $104.70K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $104.70K derived: sum of 2 quarters · filed 2019-03-06 | $104.70K derived: sum of 3 quarters · filed 2019-03-06 | $589.70K 10-K · filed 2019-03-06 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | $485.00K 10-Q · filed 2018-11-07 | $485.00K derived: sum of 4 quarters · filed 2018-11-07 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $485.00K 10-Q · filed 2018-08-03 | $485.00K derived: sum of 3 quarters · filed 2018-08-03 | $485.00K derived: sum of 4 quarters · filed 2018-08-03 | |
| 2017-03-31 | $485.00K 10-Q · filed 2018-05-08 | $485.00K derived: sum of 2 quarters · filed 2018-05-08 | $485.00K derived: sum of 3 quarters · filed 2018-05-08 | $485.00K derived: sum of 4 quarters · filed 2018-05-08 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $0.00 derived: sum of 2 quarters · filed 2018-02-26 | $0.00 derived: sum of 3 quarters · filed 2018-02-26 | $0.00 10-K · filed 2018-02-26 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $0.00 derived: sum of 2 quarters · filed 2017-11-09 | $0.00 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $0.00 10-Q · filed 2017-08-09 | |||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |